Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Japanese Society of Hypertension

References

  1. Health and Welfare Statistics Association: Cause of death. Annual statistical report of National Health Conditions. J Health Welf Stat 2003; 50 ( Suppl): 46–51 ( in Japanese).

  2. Ueshima H : Reduction of blood pressure and cardiovascular mortality in Japan. J Blood Press (Ketsuatsu) 1994; 1: 194–201 ( in Japanese).

    Google Scholar 

  3. Kubo M, Kiyohara Y, Kato I, et al: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349–2354.

    PubMed  Article  Google Scholar 

  4. Kitamura A, Iso H, Iida M, et al: Trends in the indicence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 2002; 112: 104–109.

    PubMed  Article  Google Scholar 

  5. Vital and Health Statistics Division, Statistics and Information Department, Ministry of Health, Labor and Welfare (ed): Vital Statistics of Japan 2002, Vol 1. Tokyo, Health and Welfare Statistics Association, 2004 ( in Japanese).

  6. Isomura K : Investigation of long-term follow-up system based on community, in: Annual Report of National Project Team Supported by the Research Grant for Cardiovascular Desease from Ministry of Health and Welfare, Japan in 1993. Osaka, National Cardiovascular Center, 1994 ( in Japanese).

    Google Scholar 

  7. Kimura Y, Takishita S, Muratani H, et al: Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 1998; 37: 736–745.

    CAS  PubMed  Article  Google Scholar 

  8. Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707–716.

  9. Tanizaki Y, Kiyohara Y, Kato I, et al: Relationship between blood pressure based on JNC VI classification and incidence of different types of stroke in the Hisayama study, in: The Abstract Book of the 21st Annual Scientific Meeting of Japanese Society of Hypertension. 1998, p 22 ( in Japanese).

  10. NIPPON DATA 80 Research Group: Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese. Nippon Data 80. J Hum Hypertens 2003; 17: 851–857.

  11. Tanizaki Y, Kiyohara Y, Kato I, et al: Incidence and risk factors for subtypes of cerebral infarction in a general population. The Hisayama Study. Stroke 2000; 31: 2616–2622.

    CAS  PubMed  Article  Google Scholar 

  12. Health Japan 21 Planning Committee: Report of Action Plan-Making Meeting of Health Japan 21 (National Health Promotion in the 21st Century). Tokyo, Japan Health Promotion & Fitness Foundation, 2000 ( in Japanese).

  13. Arima H, Tanizaki Y, Kiyohara Y, et al: Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly. The Hisayama Study. Arch Intern Med 2003; 163: 361–366.

    PubMed  Article  Google Scholar 

  14. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular morality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

  15. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M, for the WHO MONICA Project: Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995; 26: 361–367.

    CAS  PubMed  Article  Google Scholar 

  16. Kita Y, Okayama A, Ueshima H, et al: Stroke incidence and case fatality in Shiga, Japan 1989-1993. Int J Epidemiol 1999; 28: 1059–1065.

    CAS  PubMed  Article  Google Scholar 

  17. INTERSALT Cooperative Research Group: INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1998; 297: 319–329.

  18. Nakagawa H, Morikawa Y, Okayama A, et al: Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the INTERSALT study. J Hum Hypertens 1999; 13: 735–741.

    CAS  PubMed  Article  Google Scholar 

  19. Stamler J : INTERMAP. J Hum Hypertens 2003; 17 ( Special Issue): 587–775.

    Article  Google Scholar 

  20. Ueshima H : Long-term intervention study to prevent common disease in young and middle-aged subjects, in: Annual Report of Comprehensive and Contributory Studies in 2000. 2001 ( in Japanese).

  21. Kojima S, Funaki A, Sawabe K, Takakuwa K : Changes in dietary habit and cardiovascular disease in rural area in Akita from 1950 to 1960, in Komachi Y, Isomura K, Kojima S, Shimamoto T, Tanaka H, Ozawa H (eds): Changes in Cardiovascular Disease. Tokyo, Hokendojinsha Inc, 1987, pp 120–138 ( in Japanese).

    Google Scholar 

  22. INTERSALT Cooperative Research Group: INTERSALT. Appendix tables. J Hum Hypertens 1989; 3: 331–407.

  23. Sacks FM, Svetkey LP, Vollmer WM, et al, DASHSodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.

    CAS  PubMed  Article  Google Scholar 

  24. Research Committee of Cardiovascular Diseases Prevention: The 5th Report of National Cardiovascular Survey of Japan. Tokyo, Chuohoki Publishers, 2002 ( in Japanese).

  25. Public Health Division, Ministry of Health and Welfare: 1980 National Cardiovascular Survey of Japan. Tokyo, Japan Heart Foundation, 1982 ( in Japanese).

  26. Public Health Division, Ministry of Health and Welfare: The 4th Report of National Cardiovascular Survey of Japan. Osaka, Japan Cardiovascular Research Foundation, and Tokyo, Japanese Association for Cerebro-Cardiovascular Disease Control, 1993 ( in Japanese).

  27. Hozawa A, Ohkubo T, Kikuya M, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002; 25: 57–63.

    PubMed  Article  Google Scholar 

  28. Okubo T, Kohara T, Funahashi H, Kikuya M, Hashimoto J, Imai Y : J-HOME study: status in April 2003. Ther Res 2003; 24: 1849–1855 ( in Japanese).

    Google Scholar 

  29. Chobanian AV, Bakris GL, Black HR, et al, the National High Blood Pressure Education Program Coordination Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–2572.

    CAS  PubMed  Article  Google Scholar 

  30. Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M : INTERSALT study findings: public health and medical care implications. Hypertension 1989; 14: 570–577.

    CAS  PubMed  Article  Google Scholar 

  31. Tsunematsu N, Ueshima H, Okuda N, et al, Japanese Subgroup of INTERMAP: The actual amount of reductions in salt intake in humans on a restricted salt diet compared with those on an unrestricted salt diet: from INTERMAP JAPAN. Jpn J Cardiovasc Dis Prev 2004; 14: 149–155 ( in Japanese).

    Google Scholar 

  32. Smits P, Thien T, Van't Laar A : The cardiovascular effects of regular and decaffeinated coffee. Br J Clin Pharmacol 1985; 19: 852–854.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. Minami J, Ishimitsu T, Matsuoka H : Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 1999; 33: 586–590.

    CAS  PubMed  Article  Google Scholar 

  34. Prisant LM, Alpert BS, Robbins CB, et al: American National Standard for Nonautomated Sphygmomanometers summary report. Am J Hypertens 1995; 8: 210–213.

    CAS  PubMed  Article  Google Scholar 

  35. Menard J, Chatellier G, Day M, Vaur L : Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. J Hypertens Suppl 1994; 12 ( 8): S21–S25.

    CAS  PubMed  Google Scholar 

  36. Imai Y, Otsuka K, Kawano Y, et al, on behalf of the Japanese Society of Hypertension: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771–782.

    PubMed  Article  Google Scholar 

  37. Imai Y, Munakata M, Yoshino H, et al: Seasonal variation in blood pressure in normotensive subjects studied by home measurements. Clin Sci 1996; 95: 55–60.

    Article  Google Scholar 

  38. Kikuya M, Chonan K, Imai Y, Goto E, Ishii M : Research group to assess the validity of automated blood pressure measurement devices in Japan: accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. J Hypertens 2002; 20: 629–638.

    CAS  PubMed  Article  Google Scholar 

  39. Ishimitsu T, Matsuoka H, Minami J, Kawano Y : Investigation of usefulness of home blood pressure in patients with hypertension. Ther Res 1997; 18: 488–493 ( in Japanese).

    Google Scholar 

  40. Ishii M, Goto E : Accuracy control of home blood pressure monitor. Ther Res 1998; 19: 56–59 ( in Japanese).

    Google Scholar 

  41. Ohkubo T, Imai Y, Tsuji I, et al: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–975.

    CAS  PubMed  Article  Google Scholar 

  42. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.

  43. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  44. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

  45. Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N : Proposal of reference values for home blood pressure measurement. Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan.. Am J Hypertens 1997; 10: 409–419.

    CAS  PubMed  Google Scholar 

  46. Imai Y, Ohkubo T, Tsuji I, et al: Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. Blood Press Monit 1996; 1 ( Suppl 2): S51–S58.

    Google Scholar 

  47. Guidelines Subcommittee of the Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000). Tokyo, Japanese Society of Hypertension, 2000 ( in Japanese).

  48. Fujiwara T, Nishimura T, Ohkubo T, Imai Y : Rationale and design of HOMED-BP study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 2002; 7: 77–82.

    PubMed  Article  Google Scholar 

  49. Imai Y, Abe K, Sasaki S, et al: Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. Am J Hypertens 1990; 3: 293–301.

    CAS  PubMed  Article  Google Scholar 

  50. Imai Y, Sasaki S, Minami N, et al: The accuracy and performance of the A & D TM2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. Am J Hypertens 1992; 5: 719–726.

    CAS  PubMed  Article  Google Scholar 

  51. Kuwajima I, Nishinaga M, Kanamaru A : The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. Am J Hypertens 1998; 11: 1328–1333.

    CAS  PubMed  Article  Google Scholar 

  52. Shimada K, Imai Y, Kuwajima I, et al: Guidelines for 24-hour ambulatory blood pressure monitoring (ABPM). Jpn Circ J 2000; 64 ( Suppl 5): 1207–1248 ( in Japanese).

    Google Scholar 

  53. Sokolow M, Werdegar D, Kain HK, Hinman AT : Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 1966; 34: 279–298.

    CAS  PubMed  Article  Google Scholar 

  54. Mancia G, Zanchetti A, Agabiti-Rosei E, et al: Ambula tory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464–1470.

    CAS  PubMed  Article  Google Scholar 

  55. Imai Y, Ohkubo T, Sakuma M, et al: Predictive power of screening BP, ambulatory BP and BP measured at home for overall cardiovascular mortality: a prospective observation in a cohort of northern Japan, Ohasama. Blood Press Monit 1996; 1: 251–254.

    CAS  PubMed  Google Scholar 

  56. Ohkubo T, Hozawa A, Nagai K, et al: Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens 2000; 18: 847–854.

    CAS  PubMed  Article  Google Scholar 

  57. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C : Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103: 2579–2584.

    CAS  PubMed  Article  Google Scholar 

  58. Suzuki Y, Kuwajima I, Aono T, et al: Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-hour blood pressure. Hypertens Res 2000; 23: 323–330.

    CAS  PubMed  Article  Google Scholar 

  59. Staessen JA, Thijs L, Fagard R, et al, Systolic Hypertension in Europe Trial Investigators: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539–546.

    CAS  PubMed  Article  Google Scholar 

  60. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T : Silent cerebrovascular disease in the elderly. Correlation with ambulatory blood pressure. Hypertension 1990; 16: 692–699.

    CAS  PubMed  Article  Google Scholar 

  61. Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528–536.

    CAS  PubMed  Article  Google Scholar 

  62. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM : Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 23–29.

    CAS  PubMed  Article  Google Scholar 

  63. Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.

    CAS  PubMed  Article  Google Scholar 

  64. Shimada K, Imai Y, Kuwajima I, Abe K : Patients characteristics and effects of the long-term acting calcium channel blocker barnidipine on circadian blood pressure changes: results of the Japanese Multicenter Study on Barnidipine with Ambulatory Blood Pressure Monitoring. Blood Press Monit 2001; 6 ( Suppl 2): S25–S30.

    Google Scholar 

  65. Ohkubo T, Hozawa A, Yamaguchi J, et al: Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-hour blood pressure: the Ohasama study. J Hypertens 2002; 20: 1–7.

    Article  Google Scholar 

  66. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K : Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–135.

    CAS  PubMed  Article  Google Scholar 

  67. Ohkubo T, Imai Y, Tsuji I, et al: Relation between nocturnal decline in blood pressure and mortality: the Ohasama Study. Am J Hypertens 1997; 10: 1201–1207.

    CAS  PubMed  Article  Google Scholar 

  68. Chonan K, Hashimoto J, Ohkubo T, et al: Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the morning in hypertensive population: the Ohasama Study. Clin Exp Hypertens 2002; 24: 261–275.

    CAS  PubMed  Article  Google Scholar 

  69. Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.

    PubMed  Article  Google Scholar 

  70. Kawasaki T, Uezono K : An attempt for establishment of standard values for circadian blood pressure on the basis of clinically healthy Japanese, in Omae T, Kawasaki T (ed): Clinical Practice of Blood Pressure Monitoring. Tokyo, Igaku-Shoin Ltd, 1993, pp 181–189 ( in Japanese).

    Google Scholar 

  71. Ohkubo T, Imai Y, Tsuji I, et al: Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998; 32: 255–259.

    CAS  PubMed  Article  Google Scholar 

  72. Kikuya M, Hozawa A, Ohkubo T, et al: Prognostic significance of blood pressure and heart rate variabilities. Hypertension 2000; 36: 901–906.

    CAS  PubMed  Article  Google Scholar 

  73. World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

  74. Ueda K, Omae T, Hasuo Y, et al: Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. J Hypertens 1988; 6: 991–997.

    CAS  PubMed  Article  Google Scholar 

  75. Shimamoto K : A recent trend in management and treatment of hypertension in Japan in special reference to JNCVI. J Jpn Soc Intern Med 1999; 88: 401–405 ( in Japanese).

    CAS  Article  Google Scholar 

  76. Kassai B, Gueyffier F, Boissed J-P, Boutitie F, Cucherat M : Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56: 977–982.

    PubMed  Article  Google Scholar 

  77. Fujishima M, Kiyohara Y, Kato I, et al: Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996; 45 ( Suppl 3): S14–S16.

    CAS  PubMed  Article  Google Scholar 

  78. Committee for Statistical Survey, Japanese Society for Dialysis Therapy: The current state of dialysis treatment in Japan (as of Dec. 31, 2001). J Jpn Soc Dial Ther 2003; 36: 1–31 ( in Japanese).

  79. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.

    CAS  PubMed  Article  Google Scholar 

  80. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.

  81. Schrier RW, Estacio RO, Esler A, Mehler P : Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61: 1086–1097.

    PubMed  Article  Google Scholar 

  82. Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K : Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int Suppl 1996; 55: S57–S62.

    CAS  PubMed  Google Scholar 

  83. Brenner BM, Cooper ME, de Zeeuw D, et al, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    CAS  PubMed  Article  Google Scholar 

  84. Adler AI, Stratton IM, Neil HA, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. BMJ 2000; 321: 412–419.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D : Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100: 354–360.

    CAS  Article  PubMed  Google Scholar 

  86. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG : Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Cardiol 2002; 39: 52–54.

    PubMed  Google Scholar 

  87. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.

    CAS  PubMed  Article  Google Scholar 

  88. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D : Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–2219.

    CAS  PubMed  Article  Google Scholar 

  89. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.

    CAS  PubMed  Article  Google Scholar 

  90. Safar ME, Levy BI, Struijker-Boudier H : Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864–2869.

    PubMed  Article  Google Scholar 

  91. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–733.

    CAS  PubMed  Article  Google Scholar 

  92. Lever AF, Ramsey LE : Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571–579.

    CAS  PubMed  Article  Google Scholar 

  93. Moser M, Hebert PR : Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214–1218.

    CAS  PubMed  Article  Google Scholar 

  94. Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic reviews and meta-analysis. JAMA 1997; 277: 739–745.

    CAS  PubMed  Article  Google Scholar 

  95. Collins R, Peto R : Antihypertensive drug therapy: effects on stroke and coronary heart disease, in Swales JD (ed): Textbook of Hypertension. London, Blackwell Scientific Publication, 1994, pp 1156–1164.

    Google Scholar 

  96. Whelton PK, He J : Blood pressure reduction, in Hennekens CH (ed): Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, WB Saunders, 1999, pp 341–359.

    Google Scholar 

  97. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–839.

    CAS  PubMed  Article  Google Scholar 

  98. Health and Welfare Statistics Association: Annual Statistical Report of National Health Conditions. J Health Welf Stat 2003; 50 ( Suppl): 412–413 ( in Japanese).

  99. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.

    CAS  PubMed  Article  Google Scholar 

  100. Gueyffier F, Boutitie F, Boissel JP, et al: Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data in randomized controlled trials. Ann Intern Med 1997; 126: 761–767.

    CAS  PubMed  Article  Google Scholar 

  101. MacMahon S, Rodgers A : The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.

    CAS  PubMed  Article  Google Scholar 

  102. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–1913.

    PubMed  Article  Google Scholar 

  103. Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297.

    CAS  PubMed  Article  Google Scholar 

  104. Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    CAS  PubMed  Article  Google Scholar 

  105. Takagi S, Saitoh S, Nakano M, et al: Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. J Hypertens 2000; 18: 139–144.

    CAS  PubMed  Article  Google Scholar 

  106. PROGRESS Collaborative Study Group: Randomised trial of perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

  107. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.

  108. Zanchetti A, Hansson L, Clement D, et al, HOT Study Group: Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21: 797–804.

    CAS  PubMed  Article  Google Scholar 

  109. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

  110. Appel LJ, Moore TJ, Obarzanek E, et al, DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117–1124.

    CAS  PubMed  Article  Google Scholar 

  111. Whelton PK, Appel LJ, Espeland MA, et al: Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279: 839–846.

    CAS  PubMed  Article  Google Scholar 

  112. Arakawa K : Exercise treatment in hypertension (all of hypertension). J Clin Exp Med (Igaku No Ayumi) 1999; 189: 680–684 ( in Japanese).

    Google Scholar 

  113. Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G : Walking to work and risk for hypertension in men: the Osaka Health Survey. Ann Intern Med 1999; 130: 21–26.

    Article  Google Scholar 

  114. Neaton JD, Grimm RH Jr, Prineas RJ, et al, for the Treatment of Hypertension Study Group: Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713–724.

    CAS  PubMed  Article  Google Scholar 

  115. Singer DRJ, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA : Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension 1995; 25: 1042–1044.

    CAS  PubMed  Article  Google Scholar 

  116. Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    CAS  PubMed  Article  Google Scholar 

  117. Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003; 21: 875–886.

    CAS  PubMed  Article  Google Scholar 

  118. Julius S, Kjeldsen SE, Weber M, et al, VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    CAS  PubMed  Article  Google Scholar 

  119. Weber MA, Julius S, Kjeldsen SE, et al: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.

    CAS  PubMed  Article  Google Scholar 

  120. Fujii J, Imataka K : Maintenance of long-term treatment and compliance, in: Long-Term Treatment of Hypertension. Tokyo, Chugai Igakusha, 1988, pp 149–160 ( in Japanese).

    Google Scholar 

  121. Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid CM, ANBP2 Management Committee and Investigators : 'Reverse white-coat hypertension' in older hypertensives. J Hypertens 2002; 20: 639–644.

    CAS  PubMed  Article  Google Scholar 

  122. Saito I, Saruta T : Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens Res 2003; 26: 159–162.

    PubMed  Article  Google Scholar 

  123. Yoshida K, Matsuoka H, Omae T, Fujii J : Patient-hospital relationship and quality of life in elderly patients with hypertension. Hypertens Res 1995; 18: 77–83.

    CAS  PubMed  Article  Google Scholar 

  124. Dimenas ES, Wiklund IK, Dahlhof CG, Lindvall KG, Olofsson BK, de Faire UH : Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989; 7: 885–890.

    CAS  PubMed  Article  Google Scholar 

  125. Mikami H, Ogihara T : Quality of life in the pharmacologically treated elderly patients. Jpn J Geriat 1999; 36: 186–190 ( in Japanese).

    CAS  Article  Google Scholar 

  126. Croog SE, Levine S, Testa MA, et al: The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–1664.

    CAS  PubMed  Article  Google Scholar 

  127. Beto JA, Bansal VK : Quality of life in treatment of hypertension. A meta-analysis of clinical trials. Am J Hypertens 1992; 5: 125–133.

    CAS  PubMed  Article  Google Scholar 

  128. Hjemdahl P, Wiklund IK : Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise? J Hypertens 1992; 10: 1437–1446.

    CAS  PubMed  Article  Google Scholar 

  129. Della Chiesa A, Pfiffner D, Meier B, Hess OM : Sexual activity in hypertensive men. J Hum Hypertens 2003; 17: 515–521.

    CAS  PubMed  Article  Google Scholar 

  130. Grimm RH Jr, Grandits GA, Prineas RJ, et al: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.

    CAS  PubMed  Google Scholar 

  131. Materson BJ, Reda DJ, Cushman WC, et al, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents : Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921.

    CAS  PubMed  Article  Google Scholar 

  132. Kloner RA, Brown M, Prisant LM, Collins M, Sildenafil Study Group : Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70–73.

    CAS  PubMed  Article  Google Scholar 

  133. Eaton SB, Eaton SB 3rd, Konner MJ, Shostak M : An evolutionary perspective enhances understanding of human nutritional requirements. J Nutr 1996; 126: 1732–1740.

    CAS  PubMed  Article  Google Scholar 

  134. Office of the Measures to Fight Common Disease, Community Health, Health Promotion and Nutrition Division, Healthcare Department, Ministry of Health, Labor and Welfare: Present Status of Nutrition in Japan: Version of the 14th Year of Heisei Era. Tokyo, Dai-ichi Shuppan Publishing Co Ltd, 2004 ( in Japanese).

  135. Tochikubo O, Sasaki O, Umemura S, Kaneko Y : Management of hypertension in high school students by using new salt titrator tape. Hypertension 1986; 8: 1164–1171.

    CAS  PubMed  Article  Google Scholar 

  136. Fujita T, Ando K, Ogata E : Systemic and regional hemodynamics in patients with salt-sensitive hypertension. Hypertension 1990; 16: 235–244.

    CAS  PubMed  Article  Google Scholar 

  137. Morimoto A, Uzu T, Fujii T, et al: Sodium sensitivity and cardiovascular events with essential hypertension. Lancet 1997; 350: 1734–1737.

    CAS  PubMed  Article  Google Scholar 

  138. Fujita T, Ando K : Hemodynamic and endocrine changes associated with potassium supplementation in sodium-loaded hypertensives. Hypertension 1984; 6: 184–192.

    CAS  PubMed  Article  Google Scholar 

  139. Kawano Y, Matsuoka H, Takishita S, Omae T : Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260–265.

    CAS  PubMed  Article  Google Scholar 

  140. Iso H, Terao A, Kitamura A, et al: Calcium intake and blood pressure in seven Japanese population. Am J Epidemiol 1991; 133: 776–783.

    CAS  PubMed  Article  Google Scholar 

  141. Zhou BF, Stamler J, Dennis B, et al, for the INTERMAP Research Group : Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the last 1990s: the INTERMAP Study. J Hum Hypertens 2003; 17: 623–630.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  142. Matsuzawa Y, Inoue S, Ikeda Y, et al: New diagnostic criteria of obesity and "obesity disease". J Jpn Soc Study Obes 2000; 6: 18–28 ( in Japanese).

    Google Scholar 

  143. Miyao M, Furuta M, Sakakibara H, et al: Analysis of factors related to hypertension in Japanese middle-aged male workers. J Hum Hypertens 1992; 6: 193–197.

    CAS  PubMed  Google Scholar 

  144. Kawamura M, Adachi T, Nakajima J, Fujiwara T, Hiramori K : Factors that affect calorie-sensitive and calorie-insensitive reduction in blood pressure during shortterm calorie reduction in overweight women. Hypertension 1996; 27: 408–413.

    CAS  PubMed  Article  Google Scholar 

  145. Masuo K, Mikami H, Ogihara T, Tuck ML : Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14: 530–538.

    CAS  PubMed  Article  Google Scholar 

  146. Sasaki S, Higashi Y, Nakagawa K, et al: A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15: 302–309.

    CAS  PubMed  Article  Google Scholar 

  147. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y : Regular physical activity and coronary risk factors in Japanese men. Circulation 1998; 97: 661–665.

    CAS  PubMed  Article  Google Scholar 

  148. Tashiro E, Miura S, Koga M, et al: Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. Clin Exp Pharmacol Physiol 1993; 20: 689–696.

    CAS  PubMed  Article  Google Scholar 

  149. Ishikawa-Takata K, Ohta T, Tanaka H : How much exercise is required to reduce blood pressure in essential hypertensives: a dose-response study. Am J Hypertens 2003; 16: 629–633.

    PubMed  Article  Google Scholar 

  150. Kiyonaga A, Arakawa K, Tanaka H, Shindo M : Blood pressure and hormonal responses to aerobic exercise. Hypertension 1985; 7: 125–131.

    CAS  PubMed  Article  Google Scholar 

  151. The Japanese Society of Nephrology: Guideline for life style and dietary therapy for patients with kidney disease. Jpn J Nephrol 1997; 39: 1–37 ( in Japanese).

  152. Motoyama M, Sumani Y, Kinoshita F, et al: Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. Med Sci Sports Exerc 1998; 30: 818–823.

    CAS  PubMed  Google Scholar 

  153. Ohkubo T, Hozawa A, Nagatomi R, et al: Effects of exercise training on home blood pressure values in older adults: a randomized controlled trial. J Hypertens 2001; 19: 1045–1052.

    CAS  PubMed  Article  Google Scholar 

  154. Ueshima H, Ozawa H, Baba S, et al: Alcohol drinking and high blood pressure: data from a 1980 National Cardiovascular Survey of Japan. J Clin Epidemiol 1992; 45: 667–673.

    CAS  PubMed  Article  Google Scholar 

  155. Marmot MG, Elliott P, Shipley MJ, et al: Alcohol and blood pressure: the INTERSALT study. BMJ 1994; 308: 1263–1267.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  156. Ueshima H, Mikawa K, Baba S, et al: Effect of reduced alcohol consumption of native Japanese to American men. J Clin Epidemiol 1990; 43: 1407–1414.

    Article  Google Scholar 

  157. Kiyohara Y, Ueda K, Fujishima M : Smoking and cardiovascular disease in the general population in Japan. J Hypertens Suppl 1990; 8 ( 5): S9–S15.

    CAS  PubMed  Article  Google Scholar 

  158. Sato I, Nishida M, Okita K, et al: Beneficial effect of stopping smoking on future cardiac events in male smokers with previous myocardial infarction. Jpn Circ J 1992; 56: 217–222.

    CAS  PubMed  Article  Google Scholar 

  159. Kim MK, Sasaki S, Sasazuki S, Ohkubo S, Hayashi M, Tsugane S : Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension 2002; 40: 797–803.

    CAS  PubMed  Article  Google Scholar 

  160. Brown BG, Cheung MC, Lee AC, Zhao X-Q, Chait A : Antioxidant vitamins and lipid therapy.end of a long romance? Arterioscler Thromb Vasc Biol 2002; 22: 1535–1546.

    CAS  PubMed  Article  Google Scholar 

  161. The Eurowinter Group: Cold exposure and winter mortality from ischemic heart disease, cerebrovascular disease, respiratory disease, and all cause in warm and cold regions of Europe. Lancet 1997; 349: 1341–1346.

  162. Appel LJ, Champagne CM, Harsha DW, et al, Writing Group of the PREMIER Collaborative Research Group : Effects of comprehensive lifestyle modification on blood pressure control. JAMA 2003; 289: 2083–2093.

    PubMed  Google Scholar 

  163. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.

  164. Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076.

    CAS  PubMed  Article  Google Scholar 

  165. National Intervention Cooperative Study in Elderly Hypertensives Study Group: Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–1133.

  166. The GLANT Study Group: A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension—the GLANT study—.. Hypertens Res 1995; 18: 235–244.

  167. Saito I, Kawabe H, Saruta T, et al: Effects of antihypertensive therapy with a Ca antagonist, an ACE inhibitor and a ß-blocker. Jpn Med J (Nihon Iji Shinpo) 1994; 3683: 27–31 ( in Japanese).

    Google Scholar 

  168. Baba S, the J-MIND Study Group : Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetes. Diabetes Res Clin Pract 2001; 54: 191–201.

    CAS  PubMed  Article  Google Scholar 

  169. Yui Y, Sumiyoshi T, Kodama K, et al, The Japan Multicenter Investigation for Cardiovascular Disease-B (JMICB) Study Group: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Disease-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.

    CAS  PubMed  Article  Google Scholar 

  170. Furberg CD, Psaty BM, Meyer JV : Nifedipine. Doserelated increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1231–1232.

    Article  Google Scholar 

  171. Hayashi K, Kumagai H, Saruta T : Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116–122.

    CAS  PubMed  Article  Google Scholar 

  172. Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H : Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res 1998; 21: 215–219.

    CAS  PubMed  Article  Google Scholar 

  173. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T : Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201–208.

    CAS  PubMed  Article  Google Scholar 

  174. Pitt B, Byington RP, Furberg CD, et al: Effect of amlodipine on the progression of atheroscrelosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510.

    CAS  PubMed  Article  Google Scholar 

  175. Goldberg AI, Dunlay MC, Sweet CS : Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertens Suppl 1995; 13 ( 1): S77–S80.

    CAS  PubMed  Article  Google Scholar 

  176. Yoshinaga K, Iimura O, Saruta T, et al: Evaluation of clinical usefulness of MK-954 (losartan potassium) in patients with essential hypertension: double-blind, parallel group-comparison study using enarapril maleate as control drug. J Clin Exp Med (Igaku No Ayumi) 1995; 172: 758–823 ( in Japanese).

    Google Scholar 

  177. Arakawa K, Ogihara T, Iimura O, et al: Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension: double blind, parallel group-comparison study using enarapril maleate as control drug. J Clin Ther Med (Rinsho Iyaku) 1996; 12: 2613–2661 ( in Japanese).

    Google Scholar 

  178. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462.

    CAS  PubMed  Article  Google Scholar 

  179. Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J, the PROGRESS CT Substudy Investigators : Effects of perindopril-based blood pressure lowering and of patients characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT substudy in Japan. Hypertens Res 2004; 27: 147–156.

    CAS  PubMed  Article  Google Scholar 

  180. Saruta T, Arakawa K, Iimura O, et al: Usefulness of imidapril hydrochloride in the treatment of hypertension with special reference to dry cough: comparison with enarapril maleate: multicenter cooperative study. J New Remedies Clin (Shinyaku To Rinsho) 1998; 47: 249–282 ( in Japanese).

    Google Scholar 

  181. Shah S, Khatri T, Freis ED : Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1998; 95: 611–618.

    Article  Google Scholar 

  182. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.

    CAS  PubMed  Article  Google Scholar 

  183. Saruta T, Kageyama S, Ogihara T, et al: Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens 2004; 6: 175–185.

    CAS  Article  Google Scholar 

  184. Saruta T, Suzuki H, Kawamura M, Itoh H : Serum creatine phosphokinase levels during treatment with beta-adrenoreceptor blocking agents. J Cardiovasc Pharmacol 1985; 7: 805–808.

    CAS  PubMed  Article  Google Scholar 

  185. Goto Y, Kozu Y, Kawabe K, et al: Long-term effects of doxazosin mesylate in hypertensive patients with hypercholesterolemia or diabetes or both. J Jpn Physicians Assoc 2001; 16: 46–67 ( in Japanese).

    Google Scholar 

  186. Shinohara Y, Yoshimoto T, Fukuuchi Y, Ishigami S, Joint Committee of Stroke Guideline Development: Guideline for the Management of Stroke in Japan 2004. Tokyo, Kyowa Kikaku, 2004 ( in Japanese).

  187. Broderick JP, Adams HP Jr, Barsan W, et al: Guidelines for the management of spontaneous intracerebral hemorrhage; a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905–915.

    CAS  PubMed  Article  Google Scholar 

  188. Adams HP Jr, Brott TG, Crowell RM, et al: Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 1901–1914.

    PubMed  Article  Google Scholar 

  189. Kuriyama Y : CBF (cerebral blood flow) autoregulation and antihypertensive therapy, in Saruta T, Arakawa K, Kokubu T (supervising eds): ACE Inhibitors; Innovative Clinical Applications. Tokyo, Medical Tribune, 1990, pp 89–96 ( in Japanese).

    Google Scholar 

  190. International Society of Hypertension Writing Group: International Society of Hypertension (ISH): Statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21: 665–672.

  191. Osaki Y, Matsubayashi K, Yamasaki M, et al: Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Hypertens Res 1998; 21: 169–173.

    CAS  PubMed  Article  Google Scholar 

  192. Blood Pressure in Acute Stroke Collaboration (BASC): Interventions for Deliberating Altering Blood Pressure in Acute Stroke. The Cochrane Library, Issue 3, 2003. Oxford, Update Software, 2003.

  193. The National Institute of Neurological Disorders and Stroke: Proceedings of National Symposium on Rapid Identification and Treatment of Acute Stroke. NIH Publication 1997, No 97-4239, pp 1–183.

  194. Schrader J, Luders S, Kulschewski A, et al: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–1703.

    PubMed  Article  Google Scholar 

  195. Adams HP Jr, Adams RJ, Brott T, et al, Stroke Council of the American Stroke Association : Guidelines for the early management of patients with ischemic stroke. A scientific statement from the stroke council of the American Heart Association. Stroke 2003; 34: 1056–1083.

    PubMed  Article  Google Scholar 

  196. Irie K, Yamaguchi T, Minematsu K, Omae T : The J-curve phenomenon in stroke recurrence. Stroke 1993; 24: 1844–1849.

    CAS  PubMed  Article  Google Scholar 

  197. The INDANA Project Collaborators: Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28: 2557–2562.

  198. Tzourio C, Anderson C, Chapman N, et al, PROGRESS Collaborative Group : Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.

    CAS  PubMed  Article  Google Scholar 

  199. Fransen M, Anderson C, Chalmers J, et al: Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cere brovascular disease: a randomized controlled trial. Stroke 2003; 34: 2333–2338.

    CAS  PubMed  Article  Google Scholar 

  200. Chapman N, Huxley R, Anderson C, et al: Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS trial. Stroke 2004; 35: 116–121.

    CAS  PubMed  Article  Google Scholar 

  201. Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M : Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998; 29: 1806–1809.

    CAS  PubMed  Article  Google Scholar 

  202. Sawada T : What is asymptomatic cerebrovascular disease?— Its definition and diagnostic criteria. J Jpn Soc Intern Med 1997; 86: 725–732 ( in Japanese).

    CAS  Article  Google Scholar 

  203. Committee for Writing New Guideline for Detection of Asymptomatic Brain Diseases: Guideline for Detection of Asymptomatic Brain Diseases 2003. Hokkaido, Japanese Society for Detection of Asymptomatic Brain Diseases, 2003 ( in Japanese).

  204. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S : Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932–1939.

    CAS  PubMed  Article  Google Scholar 

  205. Vermeer SE, Hollander M, van Dijk EJ, Hoffman A, Koudstaal PJ, Breteler MM : Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–1129.

    PubMed  Article  Google Scholar 

  206. Vermeer SE, Prins ND, den Heijer T, Koudstaal PJ, Breteler MM : Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222.

    PubMed  Article  Google Scholar 

  207. Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J : Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. Stroke 2000; 31: 1646–1650.

    CAS  PubMed  Article  Google Scholar 

  208. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y : Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002; 33: 1536–1540.

    PubMed  Article  Google Scholar 

  209. Leary MC, Saver JL : Annual incidence of first silent stroke in the United States: a preliminary estimates. Cerebrovasc Dis 2003; 16: 280–285.

    PubMed  Article  Google Scholar 

  210. Ishii M : Changes and prospects of antihypertensive drug therapy. J Jpn Coll Angiol 1997; 9: 551 ( in Japanese).

    Google Scholar 

  211. Matsuzawa Y, Hisamichi S, Kita T, Ozawa H, Yamamura T : Implication of major factors contributing to the development of arteriosclerosis, in: Annual Report of National Project Team Supported by the Research Grant for Comprehensive Measures against Work Related Diseases from the Ministry of Labor, Japan in 1995, 1996 ( in Japanese).

  212. Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.

    CAS  PubMed  Article  Google Scholar 

  213. Moser M, Hebert P, Hennekens CH : An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277–1279.

    CAS  PubMed  Article  Google Scholar 

  214. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

  215. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.

    CAS  PubMed  Article  Google Scholar 

  216. Kondo J, Sone T, Tsuboi H, et al: Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 2003; 146: E20.

    PubMed  Article  CAS  Google Scholar 

  217. Japanese Beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators: Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969–973.

  218. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary event after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.

    CAS  PubMed  Article  Google Scholar 

  219. Pedersen TR : Six-year follow-up of the Norwegian Multicenter Study on Timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055–1058.

    CAS  PubMed  Article  Google Scholar 

  220. The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385–1390.

  221. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–392.

  222. Ishikawa K, Nakai S, Takenaka T, et al, on behalf of the Secondary Prevention Group : Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997; 95: 2368–2373.

    CAS  PubMed  Article  Google Scholar 

  223. Ishikawa K, Kanamasa K, Hama J, et al: Effect of beta blocker on secondary prevention in elderly patients with post-myocardial infarction. Jpn J Geriat 1997; 34: 273–277 ( in Japanese).

    CAS  Article  Google Scholar 

  224. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial—the SAVE investigation. N Engl J Med 1992; 327: 669–677.

    CAS  PubMed  Article  Google Scholar 

  225. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, Valsaltan in Acute Myocardial Infarction Trial Investigators : Valsaltan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.

    CAS  PubMed  Article  Google Scholar 

  226. Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

    CAS  PubMed  Article  Google Scholar 

  227. VA Cooperative Study Group on Hypertensive Agents: Effects of treatment on morbidity in hypertension. JAMA 1970; 213: 1143–1152.

  228. The SOLVD Investigators: The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.

  229. The SOLVD Investigators: The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.

  230. Cohn JN, Tognoni G, Valsaltan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsaltan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.

    CAS  PubMed  Article  Google Scholar 

  231. Pfeffer MA, Swedberg K, Granger CB, et al, CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.

    CAS  PubMed  Article  Google Scholar 

  232. Granger CB, McMurray JJ, Yusuf S, et al, CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.

    CAS  PubMed  Article  Google Scholar 

  233. Yusuf S, Pfeffer MA, Swedberg K, et al, CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function: the CHARM-Preserved trial. Lancet 2003; 362: 777–781.

    CAS  PubMed  Article  Google Scholar 

  234. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355.

    CAS  PubMed  Article  Google Scholar 

  235. Hjalmarson A, Goldstein S, Fagerberg B, et al, MERITHF Study Group : Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Investigation Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–1302.

    CAS  PubMed  Article  Google Scholar 

  236. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9–13.

  237. Packer M, Coats AJ, Fowler MB, et al, Carvedilol Prospective Randomized Cumulative Survival Study Group : Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–1658.

    CAS  PubMed  Article  Google Scholar 

  238. Hunt SA, Baker DW, Chin MH, et al, Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2001; 104: 2996–3007.

    CAS  PubMed  Article  Google Scholar 

  239. Packer M, O'Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–1114.

    CAS  PubMed  Article  Google Scholar 

  240. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54.

    CAS  PubMed  Article  Google Scholar 

  241. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE : A meta-analysis of the effects of treatment on left ventricular mass in essential hypertention. Am J Med 2003; 115: 41–46.

    PubMed  Article  Google Scholar 

  242. Sato A, Hayashi M, Saruta T : Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837–842.

    CAS  PubMed  Article  Google Scholar 

  243. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents : Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007–2014.

    CAS  PubMed  Article  Google Scholar 

  244. Bakris GL, Williams M, Dworkin L, et al, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group : Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661.

    CAS  PubMed  Article  Google Scholar 

  245. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.

    CAS  Article  PubMed  Google Scholar 

  246. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S : Blood pressure predicts risk of development endstage renal disease in men and women. Hypertension 2003; 41: 1341–1345.

    CAS  PubMed  Article  Google Scholar 

  247. Voyaki SM, Staessen JA, Thijs L, et al, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators : Followup of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511–519.

    CAS  PubMed  Article  Google Scholar 

  248. Vupputuri S, Batuman V, Muntner P, et al: Effects of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003; 12: 1144–1149.

    Article  CAS  Google Scholar 

  249. Levey AS, Coresh J, Balk E, et al: National Kidney Foundation Practice Guideline for Chronic Kidney Disease, Evaluation, Classification, and Stratification. Ann Intern Med 2003; 139: 137–149.

    PubMed  Article  Google Scholar 

  250. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 2003; 11: 1050–1065.

    Article  CAS  Google Scholar 

  251. Manjunath G, Tighiouart H, Coresh J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121–1129.

    PubMed  Article  Google Scholar 

  252. Ruilope L, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 2001; 12: 218–225.

    CAS  PubMed  Google Scholar 

  253. Hillege HL, Girbes ARJ, Kam PJ, et al: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203–210.

    CAS  PubMed  Article  Google Scholar 

  254. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–636.

    CAS  Article  PubMed  Google Scholar 

  255. Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47–55.

    PubMed  Article  Google Scholar 

  256. Iseki K, Ikemiya Y, Iseki C, Takishita S : Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468–1474.

    PubMed  Article  Google Scholar 

  257. Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.

    CAS  PubMed  Article  Google Scholar 

  258. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group : Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–232.

    PubMed  Article  Google Scholar 

  259. Gerstein HC, Mann JF, Yi Q, et al, HOPE Study Investigators : Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426.

    CAS  PubMed  Article  Google Scholar 

  260. Hillege HL, Fidler V, Diercks GF, et al, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group : Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782.

    CAS  PubMed  Article  Google Scholar 

  261. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S : Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962.

    PubMed  Article  Google Scholar 

  262. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD : Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498–1509.

    CAS  PubMed  Article  Google Scholar 

  263. Orth SR : Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663–1672.

    CAS  PubMed  Article  Google Scholar 

  264. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH : The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124: 627–632.

    CAS  PubMed  Article  Google Scholar 

  265. Peterson JC, Adler S, Burkart JM, et al, The Modification of Diet in Renal Disease Study Group : Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754–762.

    CAS  Article  PubMed  Google Scholar 

  266. Jafar TH, Stark PC, Schmid CH, et al, AIPRD Study Group : Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.

    CAS  Article  PubMed  Google Scholar 

  267. Wright JT Jr, Bakris G, Greene T, et al, African American Study of Kidney Disease and Hypertension Study Group : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA 2002; 288: 2421–2431.

    CAS  Article  PubMed  Google Scholar 

  268. Jafar TH, Stark PC, Schmid CH, et al, AIPRD Study Group : Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131–1140.

    CAS  PubMed  Article  Google Scholar 

  269. Ruggenenti P, Perna A, Remuzzi G, The Investigators of the GISEN Group : Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254–2261.

    CAS  PubMed  Article  Google Scholar 

  270. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA : Management of glomerular proteinuria, a commentary. J Am Soc Nephrol 2003; 14: 3217–3232.

    CAS  PubMed  Article  Google Scholar 

  271. De Zeeuw D, Remuzzi G, Parving H, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–2320.

    CAS  PubMed  Article  Google Scholar 

  272. Levey AS, Rocco MV : Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–S268.

    Article  Google Scholar 

  273. Lewis EJ, Hunsicker LG, Clarke WR, et al, Collaborative Study Group : Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

    CAS  PubMed  Article  Google Scholar 

  274. Parving HH, Lehnert H, Mortensen JB, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.

    CAS  PubMed  Article  Google Scholar 

  275. Maschio G, Alberti D, Janin G, et al, The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group : Effects of the angiotensinconverting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.

    CAS  PubMed  Article  Google Scholar 

  276. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 249: 1857–1863.

  277. PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease, a randomized double-blind trial. J Hypertens 2002; 20: 729–737.

  278. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T : Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE), a randomised controlled trial. Lancet 2003; 361: 117–124.

    CAS  PubMed  Article  Google Scholar 

  279. Keane WF, Eknoyan G : Proteinuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 35: 1004–1010.

    Article  Google Scholar 

  280. Mangrum AJ, Bakris GL : Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issue. Semin Nephrol 2004; 24: 168–175.

    CAS  PubMed  Article  Google Scholar 

  281. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH : Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211–1226.

    CAS  PubMed  Article  Google Scholar 

  282. Kumagai H, Hayashi K, Kumamaru H, Saruta T : Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000; 9: 980–985.

    Article  Google Scholar 

  283. Sato A, Hayashi K, Naruse M, Saruta T : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–68.

    CAS  Article  PubMed  Google Scholar 

  284. White WB, Duprez D, St Hillaire R, et al: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026.

    CAS  PubMed  Article  Google Scholar 

  285. Committee for Statistical Survey, Japanese Society for Dialysis Therapy (Akiba T): The Current State of Chronic Dialysis Treatment in Japan (as of December 31, 2002). Tokyo, Japanese Society for Dialysis Therapy, 2003, p 12 ( in Japanese).

  286. Zager PG, Nikolic J, Brown RH, et al: "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561–569.

    CAS  PubMed  Article  Google Scholar 

  287. Mazzuchi N, Carbonell E, Fernandes-Cean J : Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147–2154.

    CAS  PubMed  Article  Google Scholar 

  288. Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T : Interaction between hypertension and other cardiovascular risk factors in survival of hemodialyzed patients. Am J Hypertens 1996; 9: 1006–1012.

    CAS  PubMed  Article  Google Scholar 

  289. Kikuchi K, Fukiyama K : Study of cardiac function in patients with dialysis, in: Annual Report of National Project Team for Long-Term Chronic Kidney Diseases (Chronic Renal Failure) (Chief, Kurokawa K), 1998, pp 49–54 ( in Japanese).

  290. Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G : Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002; 24: 175–186.

    PubMed  Article  Google Scholar 

  291. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C : Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157–2164.

    CAS  PubMed  Article  Google Scholar 

  292. Foley RN, Herzog CA, Collins AJ : Blood pressure and long-term mortality in United States hemodialysis patients: USRDA waves 3 and 4 study. Kidney Int 2002; 62: 1784–1790.

    PubMed  Article  Google Scholar 

  293. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023–1029.

    CAS  PubMed  Article  Google Scholar 

  294. Guerin AP, Blacher J, Pannier B, Matchais SJ, Safar ME, London GM : Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 20: 987–992.

    Article  Google Scholar 

  295. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T : Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261.

    CAS  PubMed  Article  Google Scholar 

  296. Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y : A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003; 19: 59–66.

    CAS  PubMed  Google Scholar 

  297. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J : Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl 1998; 68: S125–S129.

    CAS  PubMed  Article  Google Scholar 

  298. Wheat MW : Intensive drug therapy, in Doroghazi RM, Slater E (eds): Aortic Dissection. New York, McGraw-Hill, 1983, p 165.

    Google Scholar 

  299. Pretre R, von Segesser LK : Aortic dissection. Lancet 1997; 349: 1461–1464.

    CAS  Article  PubMed  Google Scholar 

  300. Nienaber CA, Eagle KA : Aortic dissection: new frontiers in diagnosis and management. Part II: Therapeutic management and follow-up. Circulation 2003; 108: 772–778.

    PubMed  Article  Google Scholar 

  301. Iimura O : Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19 ( Suppl I): S1–S8.

    PubMed  Article  Google Scholar 

  302. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25 ( Suppl 1): S71–S73.

  303. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.

  304. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M : Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.

    CAS  PubMed  Article  Google Scholar 

  305. Nakamura Y, Saitoh S, Takagi S, et al: Cardiovascular mortality based on blood pressure classification in patients with impaired glucose tolerance. J Clin Exp Med (Igaku No Ayumi) 2004; 210: 717–718 ( in Japanese).

    Google Scholar 

  306. Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353–357.

    CAS  PubMed  Article  Google Scholar 

  307. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–1792.

  308. Viberti G, Wheeldon NM, for the Micro Albuminuria Reduction with Valsartan (MARVAL) Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressureindependent effect. Circulation 2002; 106: 672–678.

    CAS  PubMed  Article  Google Scholar 

  309. Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.

    CAS  PubMed  Article  Google Scholar 

  310. Tuomilehto J, Rastenyte D, Birkenhager WH, et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: N Engl J Med 1999; 340: 677–684.

    CAS  PubMed  Article  Google Scholar 

  311. Estacio RO, Jeffers BM, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW : The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.

    CAS  PubMed  Article  Google Scholar 

  312. Tatti P, Pahor M, Byington RP, et al: Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.

    CAS  PubMed  Article  Google Scholar 

  313. Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia—Primary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1087–1095.

    CAS  PubMed  Article  Google Scholar 

  314. Sever PS, Dahlof B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.

    CAS  PubMed  Article  Google Scholar 

  315. Health Promotion and Nutrition Division, Healthcare Department, Ministry of Health and Welfare: Present Status of Nutrition in Japan: Results from National Nutrition Survey in 1990. Tokyo, Dai-ichi Shuppan Publishing Co. Ltd., 1992, p 121 ( in Japanese).

  316. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

  317. Tanaka H, Teramoto S, Oashi K, et al: Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104: 281–285.

    CAS  PubMed  Article  Google Scholar 

  318. Kiely DG, Cargill RI, Lipworth BJ : Effects of frusemide and hypoxia on the pulmonary vascular bed in man. Br J Clin Pharmacol 1997; 43: 309–313.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  319. Fang J, Alderman MH : Serum uric acid and cardiovascular mortality. JAMA 2000; 283: 2404–2410.

    CAS  PubMed  Article  Google Scholar 

  320. Alderman MH, Cohen H, Madhaven S, Kivlighn S : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.

    CAS  PubMed  Article  Google Scholar 

  321. Choi HK, Atkinson K, Karlson EW, Whillett W, Curhan G : Alcohol intake and risk of incident gout in men: a prospective study. JAMA 2004; 363: 1277–1281.

    Google Scholar 

  322. Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000; 18: 1149–1154.

    CAS  PubMed  Article  Google Scholar 

  323. Yamanaka H, Togashi R, Hakoda M, et al: Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13–18.

    CAS  PubMed  Article  Google Scholar 

  324. Guidelines Subcommittee: Hypertension and cardiovascular damage, in: Guidelines for the Management of Hyperuricemia and Gout, 1st ed. Tokyo, Japanese Society of Gout and Nucleic Acid Metabolism, 2002, pp 51–55 ( in Japanese).

  325. Cheng JW, Zhu L, Gu MJ, Song ZM : Metaanalysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. World J Gastroenterol 2003; 9: 1836–1839.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  326. Health and Welfare Statistics Association: Health condition, medical treatment and measure against common disease. Annual Statistical Report of National Health Conditions. J Health Welf Stat 1998; 45 ( Suppl): 81–111 ( in Japanese).

  327. National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275–285.

  328. Madhavan S, Ooi WL, Cohen H, Alderman MH : Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401.

    CAS  PubMed  Article  Google Scholar 

  329. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C : Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983–988.

    CAS  PubMed  Article  Google Scholar 

  330. Imai C, Muratani H, Kimura Y, Kanzato N, Takishita S, Fukiyama K : Effect of meal ingestion and active standing on blood pressure in patients ≥60 years of age. Am J Cardiol 1998; 81: 1310–1314.

    CAS  PubMed  Article  Google Scholar 

  331. Kannel WB, D'Agostino RB, Silbershatz H : Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J 1997; 134: 758–763.

    CAS  PubMed  Article  Google Scholar 

  332. Port S, Demer L, Jennrich R, Walter D, Garfinkel A : Systolic blood pressure and mortality. Lancet 2000; 355: 175–180.

    CAS  PubMed  Article  Google Scholar 

  333. Hayakawa T, Kita Y, Okamura T, Kadowaki T, Ueshima H : Cardiovascular medicine: NIPPON DATA. Med Frontline (Saishin Igaku) 2002; 57: 1360–1368 ( in Japanese).

    Google Scholar 

  334. Takagi S, Saito S, Sakamoto K, et al: Cerebral and cardiac complication and long-term prognosis of elderly hypertensive patients—from epidemiological study of cardiovascular disease in Hokkaido—. J Blood Press (Ketsuatsu) 1995; 5: 42–47 ( in Japanese).

    Google Scholar 

  335. Shimada K, Kawano A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T : Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992; 10: 875–878.

    CAS  PubMed  Google Scholar 

  336. Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349.

    CAS  PubMed  Article  Google Scholar 

  337. Amery A, Birkenhager W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–1354.

    CAS  PubMed  Article  Google Scholar 

  338. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO : Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.

    CAS  PubMed  Article  Google Scholar 

  339. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.

  340. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

  341. Staessen JA, Fagard R, Thijs L, et al: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764.

    CAS  PubMed  Article  Google Scholar 

  342. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group : Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829.

    CAS  PubMed  Article  Google Scholar 

  343. Gong L, Zhang W, Zhu Y, et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–1245.

    CAS  PubMed  Article  Google Scholar 

  344. Insua JT, Sacks HG, Lau TS, et al: Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355–362.

    CAS  PubMed  Article  Google Scholar 

  345. Gueyffier F, Bulpitt C, Boissel J-P : Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–796.

    CAS  PubMed  Article  Google Scholar 

  346. Ogihara T, Kuramoto K : Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between-calcium antagonist and a diuretic. NICSEH study. Hypertens Res 2000; 23: 33–37.

    CAS  PubMed  Article  Google Scholar 

  347. Ogihara T, on behalf of the PATE-Hypertension Study Group in Japan: A practitioner's trial on the efficacy of antihypertensive treatment in the elderly hypertension (the PATE-Hypertension Study) in Japan. Am J Hypertens 2000; 13: 461–467.

    CAS  PubMed  Article  Google Scholar 

  348. Wing LMH, Reid CM, Ryan P, et al: A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics in the elderly (the Second Australian National Blood Pressure Study). N Engl J Med 2003; 348: 583–592.

    CAS  PubMed  Article  Google Scholar 

  349. Black HR, Elliott WJ, Weber MA, et al, for the Stage I Systolic Hypertension (SISH) Study Group : One-year study of felodipine or placebo for stage I isolated systolic hypertension. Hypertension 2001; 38: 1118–1123.

    CAS  PubMed  Article  Google Scholar 

  350. Hakala SM, Tilvis RS, Strandberg TE : Blood pressure and mortality in an older population. A 5-year follow-up of the Helsinki Aging Study. Eur Heart J 1997; 18: 1019–1023.

    CAS  PubMed  Article  Google Scholar 

  351. Ogihara T, Morimoto S, Nakahashi T, et al: Therapeutic policy for elderly hypertensives in Japan—a questionnaire survey of specialists.. Jpn J Geriat 1994; 31: 396–403 ( in Japanese).

    CAS  Article  Google Scholar 

  352. August P : Initial treatment of hypertension. N Engl J Med 2003; 348: 610–616.

    PubMed  Article  Google Scholar 

  353. Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly 2002 revised version. Hypertens Res 2003; 26: 1–36.

    PubMed  Article  Google Scholar 

  354. Perry HM Jr, Davis BR, Price TR, et al, for the Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group : Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284: 465–471.

    PubMed  Article  Google Scholar 

  355. Kjeldsen SE, Kolloch RE, Leonetti G, et al, for the HOT Study Group : Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000; 18: 629–642.

    CAS  PubMed  Article  Google Scholar 

  356. Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB : The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004–2009.

    CAS  PubMed  Article  Google Scholar 

  357. Hiwada K, Ogihara T, Matsumoto M, et al: Guidelines on treatment of hypertension in the elderly, 1999 revised edition. Jpn J Geriat 1999; 36: 576–603 ( in Japanese).

    CAS  Article  Google Scholar 

  358. Messerli FH, Grossman E, Golgbourt U : Are ß-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907.

    CAS  PubMed  Article  Google Scholar 

  359. Hansson L, Lindholm LH, Ekbom T, et al: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751–1756.

    CAS  PubMed  Article  Google Scholar 

  360. Forette F, Seux ML, Staessen JA, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.

    CAS  PubMed  Article  Google Scholar 

  361. Kuramoto K : Hypertension in the elderly and ACE inhibitor—study of age-related clinical efficacy and tolerability of captopril in 964 hypertensive patients in Japan. Intern Med (Naika) 1991; 68: 862–867 ( in Japanese).

    Google Scholar 

  362. Ogihara T, Hiwada K, Matsuoka H, et al: Guidelines on treatment of hypertension in the elderly, 1995—a tentative plan for comprehensive research projects on aging and health.. Jpn J Geriat 1996; 33: 945–975 ( in Japanese).

    CAS  Article  Google Scholar 

  363. Ogihara T, Arakawa K : Clinical efficacy and tolerability of candesartan cilexetil. J Hum Hypertens 1999; 13 ( Suppl 1): S27–S31.

    CAS  PubMed  Article  Google Scholar 

  364. Kjeldsen SE, Dahlof B, Devereux RB, et al, for the LIFE Study Group : Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002; 288: 1491–1498.

    CAS  PubMed  Article  Google Scholar 

  365. Pitt B, Poole-Wilson PA, Segal R, et al, on behalf of the ELITE II Investigators : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.

    CAS  PubMed  Article  Google Scholar 

  366. Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Research Group : Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289: 2073–2082.

    CAS  PubMed  Article  Google Scholar 

  367. Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717–725.

    PubMed  Article  Google Scholar 

  368. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R : Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601–605.

    CAS  PubMed  Article  Google Scholar 

  369. Taler SJ, Textor SC, Augustine JE : Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–988.

    CAS  PubMed  Article  Google Scholar 

  370. Ohta Y, Tsuchihashi T, Fujii K, et al: Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. J Hum Hypertens 2004; 18: 273–278.

    CAS  PubMed  Article  Google Scholar 

  371. Ono A, Fujita T : Factors relating to inadequate control of blood pressure in hypertensive outpatients. Hypertens Res 2003; 26: 219–224.

    PubMed  Article  Google Scholar 

  372. Nishizaka MK, Zaman MA, Calhoun DA : Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925–930.

    CAS  PubMed  Article  Google Scholar 

  373. Kaplan NM : Hypertensive crises, in: Clinical Hypertension, 8th ed. Baltimore, Lippincott Williams & Wilkins, 2002, pp 339–356.

    Google Scholar 

  374. Vaughan CJ, Delanty N : Hypertensive emergencies. Lancet 2000; 356: 411–417.

    CAS  Article  PubMed  Google Scholar 

  375. Sesoko S, Akema N, Matsukawa T, Kaneko Y : Predisposing factors for the development of malignant essential hypertension. Arch Intern Med 1987; 147: 1721–1724.

    CAS  PubMed  Article  Google Scholar 

  376. Ohta Y, Tsuchihashi T, Ohya Y, et al: Trends in the patho physiological characteristics of malignant hypertension. Hypertens Res 2001; 24: 489–492.

    CAS  PubMed  Article  Google Scholar 

  377. Kawazoe N, Eto T, Abe I, et al: Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis. Clin Nephrol 1988; 29: 53–57.

    CAS  PubMed  Google Scholar 

  378. Eagle KA, Berger PB, Calkins H, et al, Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002; 105: 1257–1267.

    PubMed  Article  Google Scholar 

  379. Little JW : The impact on dentistry of recent advances in the management of hypertension. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 591–599.

    CAS  PubMed  Article  Google Scholar 

  380. Tsuchihashi T, Takata Y, Kurokawa H, et al: Blood pressure response during dental surgery. Hypertens Res 1996; 19: 189–194.

    CAS  PubMed  Article  Google Scholar 

  381. Rosenthal T, Oparil S : Hypertension in women. J Hum Hypertens 2000; 14: 691–704.

    CAS  PubMed  Article  Google Scholar 

  382. Sato K : New proposal for hypertension in pregnancy. Nippon Ninnsin Chuudoku 2003; 11: 15–44 ( in Japanese).

    Google Scholar 

  383. Wallenburg HC : Prevention of pre-eclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol 2001; 94: 13–22.

    CAS  PubMed  Article  Google Scholar 

  384. Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–185.

    CAS  PubMed  Article  Google Scholar 

  385. Roberts JM, Pearson G, Cutler J, Lindheimer M : Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003; 41: 437–445.

    CAS  PubMed  Article  Google Scholar 

  386. Lewis R, Sibai BM : The use of calcium-channel blockers in pregnancy. New Horiz 1996; 4: 115–122.

    CAS  PubMed  Google Scholar 

  387. Shotan A, Wiiderhorn J, Hurst A, Elkayam U : Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96: 451–456.

    CAS  PubMed  Article  Google Scholar 

  388. NMWR: Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987-1995. JAMA 1997; 277: 1193–1194.

  389. Chasan-Taber L, Willett WC, Manson JE, et al: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483–489.

    CAS  PubMed  Article  Google Scholar 

  390. Anderson GL, Limacher M, Assaf AR, et al, Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712.

    CAS  PubMed  Article  Google Scholar 

  391. Staessen JA, Celis H, Fagard R : The epidemiology of the association between hypertension and menopause. J Hum Hypertens 1998; 12: 587–592.

    CAS  PubMed  Article  Google Scholar 

  392. Pines A, Fisman EZ : Hypertension in menopausal women—a special case, for special treatment? Gynecol Endocrinol 2001; 15: 397–405.

    CAS  PubMed  Google Scholar 

  393. Fisman EZ, Tenenbaum A, Pines A : Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4: 464–470.

    PubMed  Article  Google Scholar 

  394. Uchiyama M : Studies of blood pressures in school children in Northern Japan. Public Health 1985; 99: 18–22.

    CAS  PubMed  Article  Google Scholar 

  395. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK : Trends in blood pressure among children and adolescents. JAMA 2004; 291: 2107–2113.

    CAS  PubMed  Article  Google Scholar 

  396. Dillon MJ : Clinical aspects of hypertension, in Holliday MA (ed): Pediatric Nephrology. Baltimore, Williams & Wilkins, 1987, pp 743–757.

    Google Scholar 

  397. McCrory WW : Definition, prevalence, and distribution of causes of hypertension, in Loggie JMH (ed): Pediatric and adolescent Hypertension. Cambridge, Blackwell Scientific Publications, 1992, pp 104–111.

    Google Scholar 

  398. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–576.

  399. Murata M : Hypertension. Jpn J Pediatr (Shonika Rinsho) 1986; 39 ( Suppl): 2977–2984 ( in Japanese).

    Google Scholar 

  400. Hashimoto N, Kawasaki T, Kikuchi T, Uchiyama M : Criteria of normal blood pressure and hypertension in Japanese preschool children. J Hum Hypertens 1997; 11: 351–354.

    CAS  PubMed  Article  Google Scholar 

  401. Uchiyama M, Kikuchi T, Yamauchi K, Murata M : Validity and problem of criterion measure of blood pressure in children of Japan. J Child Health (Shoni Hoken Kenkyu) 2004; 39: 174–176 ( in Japanese).

    Google Scholar 

  402. Abe K, Nishio T, Mori C, Haneda N, Watanabe K : A longitudinal study of blood pressure, cholesterol and left ventricular muscle volume in children: the Shimane Heart Study. Acta Paediatr Jpn 1993; 35: 130–137.

    CAS  PubMed  Article  Google Scholar 

  403. Daniels SR, Witt SA, Glascock B, Khoury PR, Kimball TR : Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr 2002; 141: 186–190.

    PubMed  Article  Google Scholar 

  404. Uchiyama M : Risk factors for the development of essential hypertension: long-term follow-up study in junior high school students in Niigata, Japan. J Hum Hypertens 1994; 8: 323–325.

    CAS  PubMed  Google Scholar 

  405. Kawasaki T, Uezono K, Sanefuji M, et al: A 17-year follow-up study of hypertensive and normotensive male university students in Japan. Hypertens Res 2002; 26: 445–452.

    Article  Google Scholar 

  406. Geleijnse JM, Hofman A, Witteman JCM, Hazebroek AA, Valkenburg HA, Grobbee DE : Long-term effects of neonatal sodium restriction on blood pressure. Hypertension 1997; 29: 913–917.

    CAS  PubMed  Article  Google Scholar 

  407. Martin RM, Ness AR, Gunnell SA, Emmett P, Smith GD : Does breastfeeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Parents and Children (ALSPAC). Circulation 2004; 109: 1259–1266.

    PubMed  Article  Google Scholar 

  408. Research Committee on Serum Lipid Level Survey 1990 in Japan: Current state of and recent trends in serum lipid levels in the general Japanese population. J Atheroscler Thromb 1996; 2: 122–132.

  409. Weiss R, Dziura J, Burgert T, et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362–2374.

    CAS  PubMed  Article  Google Scholar 

  410. Kotani K, Nishida M, Yamashita S, et al: Two decades of annual medical examinations in Japanese obese children: do obese children grow into obese adults? Int J Obes Relat Metab Disord 1997; 21: 912–921.

    CAS  PubMed  Article  Google Scholar 

  411. Naganuma Y, Tomizawa S, Igarashi K, Tooyama J, Ozawa K, Uchiyama M : Usefulness of 24-hour blood pressure measurement in obese children. J Pediatr Pract (Shonika Shinryo) 1996; 59: 2084–2088 ( in Japanese).

    Google Scholar 

  412. Tomizawa S, Uchiyama M, Kurayama H, et al: Study of the dose of long-acting nifedipine (Sepamit R) in hypertensive children with renal disease. J Pediatr Pract (Shonika Shinryo) 1996; 59: 303–310 ( in Japanese).

    Google Scholar 

  413. Ingelfinger JR : When should essential hypertension in childhood be treated and how? Pediatr Nephrol 1995; 9: 552.

    CAS  PubMed  Article  Google Scholar 

  414. Gifford RW : Evaluation of the hypertensive patient with emphasis on detecting curable causes. Milbank Mem Fund Q 1969; 47: 170–186.

    Article  Google Scholar 

  415. Bech K, Hilden T : The frequency of secondary hypertension. Acta Med Scand 1975; 197: 65–69.

    CAS  PubMed  Article  Google Scholar 

  416. Ferguson RK : Cost and yield of the hypertensive evaluation. Ann Intern Med 1975; 82: 761–765.

    CAS  PubMed  Article  Google Scholar 

  417. Berglund G, Andersson O, Wilhelmsen L : Prevalence of primary and secondary hypertension: studies in a random population sample. BMJ 1976; 2: 554–556.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  418. Danielson M, Dammstrom BG : The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451–455.

    CAS  PubMed  Article  Google Scholar 

  419. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JWK : Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289–1293.

    CAS  PubMed  Article  Google Scholar 

  420. Omura M, Saita J, Yamaguchi K, Kakuta Y, Nishikawa T : Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.

    PubMed  Article  Google Scholar 

  421. Omae T : Pathophysiology and prognosis of hypertensive subjects. J Jpn Soc Intern Med (Nihon Naika Gakkai Zasshi) 1985; 74: 401–415 ( in Japanese).

    CAS  Article  Google Scholar 

  422. Hypertension in Diabetes Study (HDS): 1 Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.

  423. Dinneen SF, Gerstein HC : The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413–1418.

    CAS  PubMed  Article  Google Scholar 

  424. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M : Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993; 118: 577–581.

    CAS  PubMed  Article  Google Scholar 

  425. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R : Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982–988.

    CAS  PubMed  Article  Google Scholar 

  426. Bretzel RG : Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997; 10: 208S–217S.

    CAS  PubMed  Article  Google Scholar 

  427. Preston RA, Singer I, Epstein M : Renal parenchymal hypertension. Arch Intern Med 1996; 156: 602–611.

    CAS  PubMed  Article  Google Scholar 

  428. Nolin L, Courteau M : Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999; 70: S56–S62.

    CAS  PubMed  Article  Google Scholar 

  429. Maschio G, Cagnoli L, Claroni F, et al: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265–269.

    CAS  PubMed  Google Scholar 

  430. Higashihara E : Clinical guideline of autosomal dominant polycystic kidney disease (ADPKD). Kidney (Jinzo) 2003; 26: 71–81 ( in Japanese).

    Google Scholar 

  431. Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y : Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet 2002; 47: 51–54.

    PubMed  Article  Google Scholar 

  432. Higashihara E, Nutahara K, Kojima M, et al: Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 1998; 80: 421–427.

    CAS  PubMed  Article  Google Scholar 

  433. Higashihara E, Aso Y, Shimazaki J, Ito H, Koise K, Sakai O : Clinical aspects of polycystic kidney disease. J Urol 1992; 147: 329–332.

    CAS  PubMed  Article  Google Scholar 

  434. Torres VE, Wilson DM, Burnett JC Jr, Johnson CM, Offord KP : Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991; 66: 1010–1017.

    CAS  PubMed  Article  Google Scholar 

  435. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW : Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427–432.

    CAS  PubMed  Article  Google Scholar 

  436. Higashihara E : Reno-protective effect of anti-hypertensive drugs in autosomal dominant polycystic kidney disease (ADPKD) and preventive effects of PPARã agonist against progressive renal failure in ADPKD, in Tomino Y (ed): Annual Report of Progressive Renal Disease Research Committee Supported by the Ministry of Health, Labor, and Welfare of Japan in 2002. 2003, pp 73–76 ( in Japanese).

  437. Ruggieri PM, Poulos N, Masaryk TJ, et al: Occult intracranial aneurysms in polycystic kidney disease: screening with MR angiography. Radiology 1994; 191: 33–39.

    CAS  PubMed  Article  Google Scholar 

  438. Yamashita T, Ito F, Iwakiri N, Mitsuyama H, Fujii S, Kitabatake A : Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553–557.

    PubMed  Article  Google Scholar 

  439. Uzu T, Inoue T, Fujii T, et al: Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. Am J Kidney Dis 1997; 29: 733–738.

    CAS  PubMed  Article  Google Scholar 

  440. Preston RA, Epstein M : Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365–1377.

    CAS  PubMed  Article  Google Scholar 

  441. Tuttle KR : Screening for renal artery stenosis: hypertension and more. Am J Kidney Dis 1998; 32: 842–847.

    CAS  PubMed  Article  Google Scholar 

  442. Imai Y, Abe K, Otsuka Y, et al: Exaggerated response of renin secretion to captopril (SQ 14225) in renovascular hypertension. Jpn Heart J 1980; 21: 793–802.

    CAS  PubMed  Article  Google Scholar 

  443. Oei HY : Captopril renography. Early observation and diagnostic criteria. Am J Hypertens 1991; 4: 678S–684S.

    CAS  PubMed  Article  Google Scholar 

  444. Nally JV, Chen C, Fine E, et al: Diagnostic criteria of renovascular hypertension with captopril renography. A consensus statement. Am J Hypertens 1991; 4: 749S–752S.

    PubMed  Article  Google Scholar 

  445. Olin JW, Peidmonte MR, Young JR, DeAnna S, Grubb M, Childs MB : The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122: 833–838.

    CAS  PubMed  Article  Google Scholar 

  446. Radermacher J, Chavan A, Bleck J, et al: Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410–417.

    CAS  PubMed  Article  Google Scholar 

  447. Vasbinder GBC, Nelemans PJ, Kessels AGH, Kroon AA, de Leeuw PW, van Engelshoven JMA : Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135: 401–411.

    CAS  PubMed  Article  Google Scholar 

  448. Sos TA : Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation 1991; 83 ( Suppl I): I-162–I-166.

    CAS  Google Scholar 

  449. Tegtmeyer CJ : Percutaneous renal revascularization. Mayo Clin Proc 1995; 70: 1127–1129.

    CAS  PubMed  Article  Google Scholar 

  450. Bonelli FS, McKusick MA, Textor SC, et al: Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995; 70: 1041–1052.

    CAS  PubMed  Article  Google Scholar 

  451. Zeller T, Frank U, Muller C, et al: Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. Circulation 2003; 108: 2244–2249.

    PubMed  Article  Google Scholar 

  452. Eardley KS, Lipkin GW : Atherosclerotic renal artery stenosis: is it worth diagnosing? J Hum Hypertens 1999; 13: 217–220.

    CAS  PubMed  Article  Google Scholar 

  453. Plouin P-F, Chatellier G, Darne B, Raynaud A, for the Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group: Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis. A randomized trial. Hypertension 1998; 31: 823–829.

    CAS  PubMed  Article  Google Scholar 

  454. Soejima H, Ikegami K, Machida J, Yoshida M : Renovascular hypertension. Changes and prognosis of the surgical treatment. Jpn J Urol 1990; 81: 902–908 ( in Japanese).

    CAS  Article  Google Scholar 

  455. Ichijo T, Yamamoto N, Ueshiba H, Miyachi Y : Epidemiology of adrenal incidentaloma. Clin Endocrinol (Horumon To Rinsho) 2004; 52: 43–53 ( in Japanese).

    Google Scholar 

  456. Tsunoda K, Watanabe T, Misawa S, et al: Long-term post-operative prognosis of aldosterone producing adenoma—study of 90 cases with a mean follow-up time of 11 years. J Jpn Coll Angiol 1993; 33: 149–153 ( in Japanese).

    Google Scholar 

  457. Nishimura M, Uzu T, Fujii T, et al: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266.

    CAS  PubMed  Article  Google Scholar 

  458. Miyachi Y : Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan. 2001 ( in Japanese).

  459. Shenker Y : Medical treatment of low-renin aldosteronism. Endocrinol Metab Clin North Am 1989; 18: 415–442.

    CAS  PubMed  Article  Google Scholar 

  460. Celen O, O'Brien MJ, Melby JC, Beazly RM : Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131: 646–650.

    CAS  PubMed  Article  Google Scholar 

  461. Kaplan NM : Primary aldosteronism, in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 365–382.

    Google Scholar 

  462. Yokoyama T, Shimamoto K, Iimura O : Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism. Folia Endocrinol Jpn (Nippon Naibunpi Gakkai Zasshi) 1995; 71: 1059–1074 ( in Japanese).

    CAS  Google Scholar 

  463. Miura Y : Primary aldosteronism, in Sugimoto T, Omata M (eds): Internal Medicine, 6th ed. Tokyo, Asakura Shoten, 1995, pp 1462–1468 ( in Japanese).

    Google Scholar 

  464. Omata K, Sato T, Murakami O, Abe K, Sasano H : A case of primary aldosteronism with cortisol secretion from adenoma. Biomed Ther (Chiryogaku), 1994; 28: 1397–1400 ( in Japanese).

    Google Scholar 

  465. Miyamori I : A case of primary aldosteronism, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 227–233 ( in Japanese).

  466. Young S-C, Shionoiri H, Takasaki I, Kihara M, Gotoh E : Hypertensive complications in patients with primary aldosteronism. A retrospective study. Curr Ther Res 1991; 50: 317–325.

    Google Scholar 

  467. Nawata H : Cushing syndrome (adrenal), in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 234–240 ( in Japanese).

  468. Nawata H, Demura H, Suda T, Takayanagi R : Adrenal preclinical Cushing syndrome, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 223–236 ( in Japanese).

  469. Annual Report of Research Project for Diencephalic-Pituitary Dysfunction Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1993. 1994, pp 237–322 ( in Japanese).

  470. Nakao K : Pheochromocytoma, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 257–259 ( in Japanese).

  471. Miura Y, Yoshinaga K : Doxazosin: a newly developed, selective a1-inhibitor in the management of patients with pheochromocytoma. Am Heart J 1988; 116: 1785–1789.

    CAS  PubMed  Article  Google Scholar 

  472. Yoshinaga H, Miura Y, Sanoyama K, et al: Treatment for pheochromocytoma with doxazosin mesilate. Med Consult N Remedies (Shinryo To Shinyaku), 1988; 25: 1367–1390 ( in Japanese).

    Google Scholar 

  473. Kaplan NM : Pheochromocytoma (with a preface about incidental adrenal masses), in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 345–363.

    Google Scholar 

  474. Plouin PF, Chatellier G, Fofol I, Corvol P : Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 292: 1133–1139.

    Article  Google Scholar 

  475. Noshiro T, Honma H, Shimizu K, et al: Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Endocr J 1996; 43: 279–284.

    CAS  PubMed  Article  Google Scholar 

  476. Saito I, Ito K, Saruta T : The effect of age on blood pressure in hyperthyroidism. J Am Geriatr Soc 1985; 33: 19–22.

    CAS  PubMed  Article  Google Scholar 

  477. Ogihara T, Hata T, Maruyama A, et al: Blood pressure response to an angiotensin II antagonist in thyrotoxic patients with and without high blood pressure. Endocrinol Jpn 1980; 27: 223–227.

    CAS  PubMed  Article  Google Scholar 

  478. Saito I, Ito K, Saruta T : Hypothyroidism as a cause of hypertension. Hypertension 1983; 5: 112–115.

    CAS  PubMed  Article  Google Scholar 

  479. Brickman AS, Nyby MD : Parathyroid disease and hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, Raven Press, 1995, pp 2263–2279.

    Google Scholar 

  480. Kaplan NM : Other forms of secondary hypertension, in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 396–406.

    Google Scholar 

  481. Ishikawa K : Takayasu disease with hypertension. Spectrum-specific syndrome series 12. Syndrome in circulatory organ. Jpn J Clin Med (Nihon Rinsho), 1996; 54 ( Suppl): 118–121 ( in Japanese).

    Google Scholar 

  482. Hashimoto H : Annual Report of Immunologic Diseases Research Committee, Intractable Angitis Subcommittee Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 2001. 2002, pp 21–25 ( in Japanese).

  483. Koide K : Epidemiologic study of aortitis syndrome: number of newly developed patients and their complications, in: Annual Report of Intractable Angitis Research Committee Supported by the Research Grants from the Ministry of Health and Welfare in 1994. 1994, pp 7–10 ( in Japanese).

  484. Machida M, Sakuma M, Aoki H, Yasuda K : Long-term follow-up results of cardiac and large artery lesion complicated with Takayasu arteritis, in: Annual Report of Intractable Angitis Research Committee Supported by the Research Grants from the Ministry of Health and Welfare in 1993. 1993, pp 192–195 ( in Japanese).

  485. Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y : Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 2003; 108: 1474–1480.

    PubMed  Article  Google Scholar 

  486. Department of Disease Control and Prevention, Health Service Bureau, the Ministry of Health and Welfare (supervising ed): Periarteritis nodosa, in: Guideline for Diagnosis and Treatment for Intractable Diseases. Aichi, Roppou Publication. 1997, pp 107–115 ( in Japanese).

  487. Tolo-Salgar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH : Long-term follow-up of patients after coarctation of the aorta repair. Am J Cardiol 2002; 89: 541–547.

    Article  Google Scholar 

  488. Ross RD, Clapp SK, Gunther S, et al: Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. Am Heart J 1992; 123: 1293–1299.

    CAS  PubMed  Article  Google Scholar 

  489. Bell GM : Intracranial disorders and hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. New York, Raven Press, 1995, pp 2451–2458.

    Google Scholar 

  490. Morimoto S, Sasaki S, Takeda K, et al: Decrease in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medula in essential hypertension. Stroke 1999; 30: 1707–1710.

    CAS  PubMed  Article  Google Scholar 

  491. Johnson AG, Nguyen TV, Day RO : Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.

    CAS  PubMed  Article  Google Scholar 

  492. Phillips BB, Joss JD, Mulhausen PL : Blood pressure elevation in a patients treated with salsalate. Ann Pharmacother 2002; 36: 624–627.

    PubMed  Article  Google Scholar 

  493. Whelton A : Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 ( Suppl 5B): S13–S24.

    Article  Google Scholar 

  494. Fowles RE : Potential cardiovascular effects of COX-2 selective nonsteroidal anti-inflammatory drugs. J Pain Palliat Care Pharmacother 2003; 17: 27–50.

    PubMed  Article  Google Scholar 

  495. Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S : Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 2001; 15: 549–552.

    CAS  PubMed  Article  Google Scholar 

  496. Sigurjonsdottir HA, Manhem K, Axelson M, Wallerstedt S : Subjects with essential hypertension are more sensitive to the inhibition of 11β-HSD by liquorice. J Hum Hypertens 2003; 17: 125–131.

    CAS  PubMed  Article  Google Scholar 

  497. Sato A, Funder JW, Okubo M, Kubota E, Saruta T : Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995; 8: 823–828.

    CAS  PubMed  Article  Google Scholar 

  498. Whitworth JA, Mangos GJ, Kelly JJ : Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36: 912–916.

    CAS  PubMed  Article  Google Scholar 

  499. Saruta T : Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1–8.

    CAS  PubMed  Article  Google Scholar 

  500. Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GL, Kelly JJ : The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 2002; 20: 1035–1043.

    CAS  PubMed  Article  Google Scholar 

  501. Iuchi T, Akaike M, Mitsui T, et al: Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92: 81–87.

    CAS  PubMed  Article  Google Scholar 

  502. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA : Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19: 567–574.

    CAS  PubMed  Article  Google Scholar 

  503. Luke RG : Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4: 468–471.

    CAS  PubMed  Article  Google Scholar 

  504. Suzuki M, Gouya T : Survey for development of guideline for criteria of EPO use, in: Annual Report of Medical Research Committee on Renal Failure Supported by the Ministry of Health, Labor, and Welfare of Japan in 1992. 1993, pp 165–172 ( in Japanese).

  505. Miyashita K, Tojo A, Kimura K, et al: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004; 27: 79–84.

    CAS  PubMed  Article  Google Scholar 

  506. Kuriyama S, Hopp L, Yoshida H, et al: Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9: 426–431.

    CAS  PubMed  Article  Google Scholar 

  507. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S : Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1993; 94: 401–406.

    CAS  PubMed  Article  Google Scholar 

  508. Hui KK : Hypertensive crisis induced by interaction of clonidine with imipramine. J Am Geriatr Soc 1983; 31: 164–165.

    CAS  PubMed  Article  Google Scholar 

  509. Abo-Zena RA, Bobek MB, Dweik RA : Hypertensive urgency induced by an interaction of mirtazapine and clonidine. Pharmacotherapy 2000; 20: 476–478.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Consortia

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Guidelines for the Management of Hypertension (JSH 2004). Japanese Society of Hypertension. Hypertens Res 29, S1–S105 (2006). https://doi.org/10.1038/hr.2006.143

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/hr.2006.143

Search

Quick links